share_log

Actinium Pharmaceuticals' Phase 3 Trial Data for Iomab-B Accepted for Presentation at Medical Conference

Actinium Pharmaceuticals' Phase 3 Trial Data for Iomab-B Accepted for Presentation at Medical Conference

藥品的 IOMAB-B 的 3 期試驗數據被接受在醫療會議上演示
MT Newswires ·  2023/01/12 13:32

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論